The Therapeutic Role of d-Cycloserine in Schizophrenia.

[1]  E. Storch,et al.  A Meta-Analysis of D-Cycloserine in Exposure-Based Treatment: Moderators of Treatment Efficacy, Response, and Diagnostic Remission. , 2017, The Journal of clinical psychiatry.

[2]  D. McKinzie,et al.  Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia , 2015, Biological Psychiatry.

[3]  Daniel H. Mathalon,et al.  Augmenting NMDA receptor signaling boosts experience-dependent neuroplasticity in the adult human brain , 2015, Proceedings of the National Academy of Sciences.

[4]  P. Stanton,et al.  The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus , 2015, Neuroscience.

[5]  Michael M. Halassa,et al.  The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia , 2015, Schizophrenia Research.

[6]  G. Andersson,et al.  D-Cycloserine vs Placebo as Adjunct to Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder and Interaction With Antidepressants: A Randomized Clinical Trial. , 2015, JAMA psychiatry.

[7]  Dan J Stein,et al.  Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders. , 2015, The Cochrane database of systematic reviews.

[8]  J. Coyle,et al.  Neuronal serine racemase regulates extracellular d-serine levels in the adult mouse hippocampus , 2015, Journal of Neural Transmission.

[9]  J. Coyle,et al.  The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond. , 2015, Current opinion in pharmacology.

[10]  M. Owen,et al.  Genetic Risk for Schizophrenia: Convergence on Synaptic Pathways Involved in Plasticity , 2015, Biological Psychiatry.

[11]  J. Lieberman,et al.  Placebo response in antipsychotic clinical trials: a meta-analysis. , 2014, JAMA psychiatry.

[12]  M. Kohler,et al.  Complex associative memory processing and sleep: A systematic review and meta-analysis of behavioural evidence and underlying EEG mechanisms , 2014, Neuroscience & Biobehavioral Reviews.

[13]  W. Lu,et al.  Glycine Induces Bidirectional Modifications in N-Methyl-d-aspartate Receptor-mediated Synaptic Responses in Hippocampal CA1 Neurons* , 2014, The Journal of Biological Chemistry.

[14]  C. Spencer,et al.  Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.

[15]  E. J. Donzis,et al.  d-Cycloserine enhances both intrinsic excitability of CA1 hippocampal neurons and expression of activity-regulated cytoskeletal (Arc) protein , 2014, Neuroscience Letters.

[16]  D. Goff.  Bitopertin: the good news and bad news. , 2014, JAMA psychiatry.

[17]  M. Ostland,et al.  Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. , 2014, JAMA psychiatry.

[18]  Xiaobai Li,et al.  Effects of prenatal chronic mild stress exposure on hippocampal cell proliferation, expression of GSK-3α, β and NR2B in adult offspring during fear extinction in rats , 2014, International Journal of Developmental Neuroscience.

[19]  Guimin Gao,et al.  Methylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insults. , 2014, JAMA psychiatry.

[20]  D. Goff,et al.  d-Cycloserine augmentation of cognitive remediation in schizophrenia , 2014, Schizophrenia Research.

[21]  A. Corvin,et al.  Genome-wide Association Studies: Findings at the Major Histocompatibility Complex Locus in Psychosis , 2014, Biological Psychiatry.

[22]  A. McAllister.  Major Histocompatibility Complex I in Brain Development and Schizophrenia , 2014, Biological Psychiatry.

[23]  S. Dravid,et al.  GluN2C/GluN2D subunit‐selective NMDA receptor potentiator CIQ reverses MK‐801‐induced impairment in prepulse inhibition and working memory in Y‐maze test in mice , 2014, British journal of pharmacology.

[24]  O. Paulsen,et al.  GluN2A and GluN2B subunit-containing NMDA receptors in hippocampal plasticity , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.

[25]  Michael F. Green,et al.  Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. , 2013, JAMA psychiatry.

[26]  J. Lindenmayer,et al.  Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo , 2013, Schizophrenia Research.

[27]  T. Large,et al.  Effects of D-amino acid oxidase inhibition on memory performance and long-term potentiation in vivo , 2013, Pharmacology research & perspectives.

[28]  J. Born,et al.  Sleep-Dependent Declarative Memory Consolidation—Unaffected after Blocking NMDA or AMPA Receptors but Enhanced by NMDA Coagonist D-Cycloserine , 2013, Neuropsychopharmacology.

[29]  Xiaobai Li,et al.  The effects of intra-hippocampal microinfusion of d-cycloserine on fear extinction, and the expression of NMDA receptor subunit NR2B and neurogenesis in the hippocampus in rats , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[30]  Mark B. Powers,et al.  D-Cycloserine Enhancement of Fear Extinction is Specific to Successful Exposure Sessions: Evidence from the Treatment of Height Phobia , 2013, Biological Psychiatry.

[31]  S. Dravid,et al.  Effect of D‐cycloserine in conjunction with fear extinction training on extracellular signal‐regulated kinase activation in the medial prefrontal cortex and amygdala in rat , 2013, The European journal of neuroscience.

[32]  B. Cooper,et al.  Peripheral administration of d-cycloserine rescues memory consolidation following bacterial endotoxin exposure , 2013, Behavioural Brain Research.

[33]  P. Fitzgerald,et al.  A Review of Evidence Linking Disrupted Neural Plasticity to Schizophrenia , 2013, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[34]  Catherine A. Hartley,et al.  Altered fear learning across development in both mouse and human , 2012, Proceedings of the National Academy of Sciences.

[35]  E. Luby,et al.  Phencyclidine/schizophrenia: one view toward the past, the other to the future. , 2012, Schizophrenia bulletin.

[36]  D. Goff,et al.  Failure of neural responses to safety cues in schizophrenia. , 2012, Archives of general psychiatry.

[37]  G. Tononi,et al.  Reduced natural oscillatory frequency of frontal thalamocortical circuits in schizophrenia. , 2012, Archives of general psychiatry.

[38]  L. P. Kate,et al.  Genetic risk , 2012, Journal of Community Genetics.

[39]  D. Javitt,et al.  A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. , 2012, The Journal of clinical psychiatry.

[40]  M. Holtze,et al.  Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. , 2012, Schizophrenia bulletin.

[41]  S. Dravid,et al.  Deletion of Glutamate Delta-1 Receptor in Mouse Leads to Aberrant Emotional and Social Behaviors , 2012, PloS one.

[42]  S. Yamamura,et al.  Clozapine, but not haloperidol, enhances glial d‐serine and L‐glutamate release in rat frontal cortex and primary cultured astrocytes , 2012, British journal of pharmacology.

[43]  Y. Ichitani,et al.  d-Cycloserine enhances spatial memory in spontaneous place recognition in rats , 2012, Neuroscience Letters.

[44]  N. Volkow,et al.  D‐cycloserine facilitates extinction of cocaine self‐administration in rats , 2011, Synapse.

[45]  D. Goff,et al.  d-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia , 2011, Schizophrenia Research.

[46]  S. Dravid,et al.  Behavioral analysis of NR2C knockout mouse reveals deficit in acquisition of conditioned fear and working memory , 2011, Neurobiology of Learning and Memory.

[47]  P. Gebicke-haerter,et al.  Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain , 2011, Psychopharmacology.

[48]  Laura Kaddour,et al.  D-cycloserine enhances memory consolidation in the plus-maze retest paradigm. , 2011, Behavioral neuroscience.

[49]  J. Coyle,et al.  Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia , 2011, Neuroscience & Biobehavioral Reviews.

[50]  G. Köhr,et al.  Triheteromeric NR1/NR2A/NR2B Receptors Constitute the Major N-Methyl-d-aspartate Receptor Population in Adult Hippocampal Synapses , 2010, The Journal of Biological Chemistry.

[51]  J. Kim,et al.  Impaired Extinction Retention in Adolescent Rats: Effects of D-Cycloserine , 2010, Neuropsychopharmacology.

[52]  K. Kendrick,et al.  The N-Methyl-D-Aspartate Receptor Co-agonist D-Cycloserine Facilitates Declarative Learning and Hippocampal Activity in Humans , 2010, Biological Psychiatry.

[53]  Y. Shoshan,et al.  D-cycloserine improves functional outcome after traumatic brain injury with wide therapeutic window. , 2010, European journal of pharmacology.

[54]  Matthew T. Geballe,et al.  Structural Determinants of d-Cycloserine Efficacy at the NR1/NR2C NMDA Receptors , 2010, The Journal of Neuroscience.

[55]  G. Hardingham.  Coupling of the NMDA receptor to neuroprotective and neurodestructive events. , 2009, Biochemical Society transactions.

[56]  R. Llinás,et al.  Inhibition of NMDARs in the Nucleus Reticularis of the Thalamus Produces Delta Frequency Bursting , 2009, Front. Neural Circuits.

[57]  D. Lewis.  Neuroplasticity of excitatory and inhibitory cortical circuits in schizophrenia , 2009, Dialogues in clinical neuroscience.

[58]  K. Roche,et al.  Growth Factor-Dependent Trafficking of Cerebellar NMDA Receptors via Protein Kinase B/Akt Phosphorylation of NR2C , 2009, Neuron.

[59]  J. Tiihonen,et al.  The efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis , 2009, Schizophrenia Research.

[60]  K. Bath,et al.  Variant BDNF Val66Met Polymorphism Affects Extinction of Conditioned Aversive Memory , 2009, The Journal of Neuroscience.

[61]  J. Houlé,et al.  NMDA receptor subunit expression in GABAergic interneurons in the prefrontal cortex: Application of laser microdissection technique , 2009, Journal of Neuroscience Methods.

[62]  P. Gean,et al.  Augmentation of Fear Extinction by D-Cycloserine is Blocked by Proteasome Inhibitors , 2008, Neuropsychopharmacology.

[63]  D. Goff,et al.  Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study , 2008, Schizophrenia Research.

[64]  Jasper A. J. Smits,et al.  Effects of D-Cycloserine Administration on Weekly Nonemotional Memory Tasks in Healthy Participants , 2008, Psychotherapy and Psychosomatics.

[65]  J. Meador-Woodruff,et al.  Lamina-Specific Abnormalities of NMDA Receptor-Associated Postsynaptic Protein Transcripts in the Prefrontal Cortex in Schizophrenia and Bipolar Disorder , 2008, Neuropsychopharmacology.

[66]  J. Krystal,et al.  A Meta-Analysis of D-Cycloserine and the Facilitation of Fear Extinction and Exposure Therapy , 2008, Biological Psychiatry.

[67]  Stefan Klöppel,et al.  The NMDA Agonist D-Cycloserine Facilitates Fear Memory Consolidation in Humans , 2008, Cerebral cortex.

[68]  D. Javitt,et al.  Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia , 2008, Trends in Neurosciences.

[69]  R. Richardson,et al.  D-Cycloserine Facilitates Extinction the First Time but not the Second Time: An Examination of the Role of NMDA Across the Course of Repeated Extinction Sessions , 2008, Neuropsychopharmacology.

[70]  Q. Pittman,et al.  Neonatal inflammation produces selective behavioural deficits and alters N‐methyl‐d‐aspartate receptor subunit mRNA in the adult rat brain , 2008, The European journal of neuroscience.

[71]  D. Goff,et al.  Lamotrigine as Add-On Therapy in Schizophrenia: Results of 2 Placebo-Controlled Trials , 2007, Journal of clinical psychopharmacology.

[72]  R. Richardson,et al.  Effects of D-Cycloserine on Extinction: Consequences of Prior Exposure to Imipramine , 2007, Biological Psychiatry.

[73]  D. Javitt,et al.  The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. , 2007, The American journal of psychiatry.

[74]  S. Mosolov,et al.  Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.

[75]  Anat Biegon,et al.  D‐cycloserine improves functional recovery and reinstates long‐term potentiation (LTP) in a mouse model of closed head injury , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[76]  Ann Marie Craig,et al.  NMDA Receptor Subunits Have Differential Roles in Mediating Excitotoxic Neuronal Death Both In Vitro and In Vivo , 2007, The Journal of Neuroscience.

[77]  Jason M. Lawrence,et al.  Evidence from gene knockout studies implicates Asc‐1 as the primary transporter mediating d‐serine reuptake in the mouse CNS , 2007, The European journal of neuroscience.

[78]  Jun Cheng,et al.  Novel regional and developmental NMDA receptor expression patterns uncovered in NR2C subunit-β-galactosidase knock-in mice , 2007, Molecular and Cellular Neuroscience.

[79]  P. Gean,et al.  Extinction Training in Conjunction with a Partial Agonist of the Glycine Site on the NMDA Receptor Erases Memory Trace , 2006, The Journal of Neuroscience.

[80]  Rick Richardson,et al.  Effects of D-Cycloserine on Extinction: Translation From Preclinical to Clinical Work , 2006, Biological Psychiatry.

[81]  Paul J Carlson,et al.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.

[82]  Yue-Cune Chang,et al.  D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia , 2006, Biological Psychiatry.

[83]  Michael J. Gutnick,et al.  NMDA Receptors in Layer 4 Spiny Stellate Cells of the Mouse Barrel Cortex Contain the NR2C Subunit , 2006, The Journal of Neuroscience.

[84]  R. Richardson,et al.  Effects of multiple exposures to d-cycloserine on extinction of conditioned fear in rats , 2005, Neurobiology of Learning and Memory.

[85]  R. Richardson,et al.  d-cycloserine facilitates extinction of learned fear: Effects on reacquisition and generalized extinction , 2005, Biological Psychiatry.

[86]  D. Cyril D’Souza,et al.  Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects , 2005, Psychopharmacology.

[87]  D. Goff,et al.  A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients , 2005, Psychopharmacology.

[88]  Daniel C. Javitt,et al.  D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia , 2005, Biological Psychiatry.

[89]  D. Javitt,et al.  Inhibition of System A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action , 2005, Molecular Psychiatry.

[90]  P. Renshaw,et al.  Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of d-cycloserine , 2005, Psychiatry Research: Neuroimaging.

[91]  J. Tiihonen,et al.  Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis , 2005, Schizophrenia Research.

[92]  J. Corwin,et al.  Effects of d-cycloserine on negative symptoms in schizophrenia , 2004, Schizophrenia Research.

[93]  Barbara O Rothbaum,et al.  Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. , 2004, Archives of general psychiatry.

[94]  Walter Paulus,et al.  Consolidation of Human Motor Cortical Neuroplasticity by D-Cycloserine , 2004, Neuropsychopharmacology.

[95]  T. Woo,et al.  Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. , 2004, Archives of general psychiatry.

[96]  C. Chiu,et al.  Characterization and localization of a human serine racemase. , 2004, Brain research. Molecular brain research.

[97]  M. Martina,et al.  Glycine transporter type 1 blockade changes NMDA receptor‐mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels , 2004, The Journal of physiology.

[98]  D. Goff,et al.  d-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia , 2002, Schizophrenia Research.

[99]  G. Breese,et al.  Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness , 2002, Neuroscience & Biobehavioral Reviews.

[100]  P. Renshaw,et al.  Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine , 2002, Biological Psychiatry.

[101]  D. Javitt,et al.  Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. , 2002, The American journal of psychiatry.

[102]  D. Javitt,et al.  Adjunctive high-dose glycine in the treatment of schizophrenia. , 2001, The international journal of neuropsychopharmacology.

[103]  J. Coyle,et al.  The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. , 2001, The American journal of psychiatry.

[104]  D. Goff,et al.  Placebo-controlled trial of glycine added to clozapine in schizophrenia. , 2000, The American journal of psychiatry.

[105]  J. Krystal,et al.  Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. , 2000, Archives of general psychiatry.

[106]  J. Coyle,et al.  D-serine added to clozapine for the treatment of schizophrenia. , 1999, The American journal of psychiatry.

[107]  E. Shimizu,et al.  Genetic enhancement of learning and memory in mice , 1999, Nature.

[108]  Marc G Caron,et al.  Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia , 1999, Cell.

[109]  R. Kahn,et al.  D-Cycloserine Increases Positive Symptoms in Chronic Schizophrenic Patients When Administered in Addition to Antipsychotics: A Double-Blind, Parallel, Placebo-Controlled Study , 1999, Neuropsychopharmacology.

[110]  D. Goff,et al.  A placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia , 1999, Biological Psychiatry.

[111]  Nicholas Lange,et al.  D-serine added to antipsychotics for the treatment of schizophrenia , 1998, Biological Psychiatry.

[112]  D. Javitt,et al.  Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. , 1998, The international journal of neuropsychopharmacology.

[113]  A. Malhotra,et al.  Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach , 1998, Synapse.

[114]  A. Malhotra,et al.  Clozapine Blunts N-Methyl-d-Aspartate Antagonist-Induced Psychosis: A Study with Ketamine , 1997, Biological Psychiatry.

[115]  Anil K Malhotra,et al.  Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics , 1997, Neuropsychopharmacology.

[116]  H. Westenberg,et al.  Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients , 1996, Biological Psychiatry.

[117]  J. Coyle,et al.  D-cycloserine added to clozapine for patients with schizophrenia. , 1996, The American journal of psychiatry.

[118]  D. Javitt,et al.  Double-Blind, Placebo-Controlled, Crossover Trial of Glycine Adjuvant Therapy for Treatment-Resistant Schizophrenia , 1996, British Journal of Psychiatry.

[119]  J. Kleinman,et al.  Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. , 1995, Archives of general psychiatry.

[120]  Carol A. Tamminga,et al.  Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.

[121]  J. Coyle,et al.  Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. , 1995, The American journal of psychiatry.

[122]  D. Javitt,et al.  Amelioration of negative symptoms in schizophrenia by glycine. , 1994, The American journal of psychiatry.

[123]  D. Quartermain,et al.  Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. , 1994, European journal of pharmacology.

[124]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[125]  B. Sakmann,et al.  Developmental and regional expression in the rat brain and functional properties of four NMDA receptors , 1994, Neuron.

[126]  J. Morley,et al.  Effect on memory processing by D-cycloserine, an agonist of the NMDA/glycine receptor. , 1992, European journal of pharmacology.

[127]  John F. Disterhoft,et al.  Hippocampus-dependent learning facilitated by a monoclonal antibody or D-cycloserine , 1992, Nature.

[128]  Brian A. Lawlor,et al.  Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease? , 1992, Biological Psychiatry.

[129]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[130]  E. Smeraldi,et al.  Amino acid patterns in schizophrenia: Some new findings , 1990, Psychiatry Research.

[131]  S. Potkin,et al.  An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics. , 1990, Journal of clinical psychopharmacology.

[132]  G. Handelmann,et al.  D-cycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats , 1989, Pharmacology Biochemistry and Behavior.

[133]  S. Deutsch,et al.  Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. , 1989, Clinical neuropharmacology.

[134]  R. Waziri.  Glycine Therapy of Schizophrenia , 1988, Biological Psychiatry.

[135]  A. D. Allen.  Creation, evolution, and biological psychiatry , 1988, Biological Psychiatry.

[136]  G. Sedvall,et al.  Plasma Amino Acids in Relation to Cerebrospinal Fluid Monoamine Metabolites in Schizophrenic Patients and Healthy Controls , 1985, British Journal of Psychiatry.

[137]  T. Perry.  Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction , 1982, Neuroscience Letters.

[138]  H. H. Kornhuber,et al.  Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia , 1980, Neuroscience Letters.

[139]  T. Itil,et al.  Effect of Phencyclidine in Chronic Schizophrenics * , 1967, Canadian Psychiatric Association journal.

[140]  G. Rosenbaum,et al.  Study of a new schizophrenomimetic drug; sernyl. , 1959, A.M.A. archives of neurology and psychiatry.

[141]  P. Szepetowski.  NMDA Receptors , 2017, Methods in Molecular Biology.

[142]  M. Rushworth,et al.  A Role Beyond Learning for NMDA Receptors in Reward-Based Decision-Making—a Pharmacological Study Using d-Cycloserine , 2014, Neuropsychopharmacology.

[143]  J. Pandit,et al.  Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks. , 2013, Current topics in medicinal chemistry.

[144]  Robert Stickgold,et al.  Reduced overnight consolidation of procedural learning in chronic medicated schizophrenia is related to specific sleep stages. , 2010, Journal of psychiatric research.

[145]  J. Ballenger.  A Randomized Trial of an N-methyl-d-aspartate Antagonist in Treatment-Resistant Major DepressionZarate CA, Singh JB, Carlson PJ, et al (NIH, Bethesda, Md) Arch Gen Psychiatry 63:856–864, 2006§ , 2008 .

[146]  David Wechsler,et al.  Wechsler Memory scale. , 2005 .

[147]  E. Smeraldi,et al.  d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study , 2005, Journal of Neural Transmission / General Section JNT.

[148]  J. Coyle,et al.  A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. , 1999, Archives of general psychiatry.

[149]  D. Javitt,et al.  Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. , 1999, Archives of general psychiatry.

[150]  T. Itil,et al.  d-Cycloserine therapy of psychosis by symptom provocation. , 1970, Comprehensive psychiatry.

[151]  L. Eidus,et al.  Deterioration of cycloserine in the tropics. , 1968, Bulletin of the World Health Organization.